From Good Morning America.

Eli Lilly says a new pill for obesity, similar to existing GLP-1 medications that can only be injected, is showing promise in a clinical trial.

Eli Lilly, the maker of Mounjaro and Zepbound, said Thursday that the company’s new orforglipron pill can offer up to an average of 27.3 pounds of weight loss, according to results from the first of two of its Phase 3 trials that included more than 3,100 overweight or obese adults.

READ more from GMA: https://tinyurl.com/5dm9uz86

SUBSCRIBE to GMA on YouTube: https://bit.ly/2Zq0dU5

SIGN UP to get the daily GMA Wake-Up Newsletter:
https://tinyurl.com/yc34mz6t

VISIT GMA: https://www.goodmorningamerica.com

FOLLOW:
TikTok: https://tiktok.com/@gma
Instagram: https://instagram.com/GoodMorningAmerica
Facebook: https://facebook.com/GoodMorningAmerica
Threads: https://www.threads.net/@goodmorningamerica
X: https://twitter.com/gma